Home  |  Top News  |  Most Popular  |  Video  |  Multimedia  |  News Feeds  |  Feedback
  Medicine  |  Nature & Earth  |  Biology  |  Technology & Engineering  |  Space & Planetary  |  Psychology  |  Physics & Chemistry  |  Economics  |  Archaeology
Top > Medicine, Health Care > The Mu Opioid Receptor Genotype… >
The Mu Opioid Receptor Genotype May Be a Marker for Those Who Drink for Alcohol's Rewarding Effects

Published: December 15, 2012.
By Alcoholism: Clinical & Experimental Research

Previous research had identified an individual's subjective response to alcohol as a marker of alcoholism risk. The A118G single nucleotide polymorphism (SNP) of the mu opioid receptor (OPRM1) gene had also been previously associated with subjective response to alcohol in heavy drinkers. A new study extends this research, showing that the OPRM1 genotype seems to moderate the pleasant and stimulating effects to alcohol among alcohol-dependent (AD) individuals but not its unpleasant and sedative effects.

Results will be published in a special online issue of Alcoholism: Clinical & Experimental Research and are currently available at Early View.

"People's response to drugs of abuse, including alcohol, varies dramatically," said Lara A. Ray, assistant professor in the department of psychology at the University of California, Los Angeles as well as corresponding author for the study. "Some research has suggested that the quality and intensity of a person's response to alcohol can predict whether they develop problems with alcohol. For example, individuals who experience stronger stimulant and rewarding effects from alcohol are more likely to drink heavily, thus increasing their chances of developing an alcohol use disorder.

"We have known for a long time that alcoholism runs in families, which implies a genetic risk," said Dr. Raymond F. Anton, Distinguished Professor and director of the Center for Drug and Alcohol Programs at the Medical University of South Carolina. "There is currently great interest in how medications work in different people based on their individual genetic makeup, which is called 'personalized medicine.' If you think about it, alcohol is a pharmacological agent that works on the brain in certain defined ways which we know about. So it would make sense that it would work differently in different people, most of which is likely based on genetic differences."

"The opioid system has been shown to be partially responsible for the rewarding effects of alcohol," added Ray. "We were interested in whether a mutation in this system, specifically in the OPRM1gene, would change the way AD individuals respond to alcohol in the lab. We knew that as alcoholism progresses, the rewarding effects of alcohol become less salient; AD patients tell us they mostly drink to feel normal as opposed to drinking to feel good."

Ray and her colleagues recruited 295 non-treatment seeking problem drinkers (217 males, 78 females) from the Los Angeles community through print and online advertisements. Participants were between 21 and 65 years of age, had self-identified problems with alcohol, and were consuming a minimum of 48 standard drinks per month. Of these, 43 individuals with AD, balanced for the genotype of interest (23 A-allele carriers and 20 G-allele carriers), completed two sessions of either intravenous alcohol (0.06 g/dl) or saline. Subjective responses were measured during the alcohol and saline sessions.

"AD carriers of the G-allele of the OPRM1 gene showed a greater response to alcohol in terms of stimulation, vigor, and positive mood, as compared to A-allele homozygotes," said Ray. "However the increased response was selective, such that carriers of the G allele did not differ in terms of their sedative response or craving during the alcohol administration. We also observed a trend-level effect such that those participants who were more severely AD had a greater reduction in tension in response to the alcohol compared to less-severe participants. Together, we believe these findings help connect genetics and neuroscience of alcoholism by demonstrating a role for disease severity in clinical samples."

"This variant of the opiate receptor gene is the exact same one that predicts naltrexone response," said Anton, "and which exists in about 25 percent of Caucasians. The data support the idea that alcohol might work through the brain opiate system to hypothetically increase dopamine and thereby lead to perceived positive aspects of alcohol consumption. It would also provide a reason as to why naltrexone – which blocks this effect – might break the link between alcohol-induced stimulation and further drinking as shown by myself and others. So what we have is a better understanding of a biological process that makes sense clinically and therapeutically."

"The gene we investigated, OPRM1, has received considerable attention in the alcohol research field both in terms of risk for alcoholism and for responsiveness to treatment with naltrexone," noted Ray. "This study is the first to have tested the effects of this gene on response to alcohol in AD individuals. Furthermore, the finding that more severely AD patients exhibited greater reduction in tension in response to alcohol supports the theory that as alcoholism progresses, people are driven to drink primarily for negative reinforcement, namely, alleviation of negative mood or aversive physiological states from abstinence. On a related note, patients in the early stages of alcoholism or who report drinking for reward, or to 'feel good,' may be especially good candidates for an opioid blocker such as naltrexone or possible nalmefeme."

"What these data show, and something I have been talking about for a long time, is the need for the research field to invest heavily in understanding alcohol by gene interactions," added Anton. "There should be a large-scale national study to evaluate thousands of individuals like the ones studied here. We have the genetic tools and the clinical research methods to make the link between individual differences and alcohol response/effects – which lies at the root cause of why some people become dependent/addicted and others do not."


Show Reference »


Translate this page: Chinese French German Italian Japanese Korean Portuguese Russian Spanish


 
All comments are reviewed before being posted. We cannot accept messages that refer a product, or web site.If you are looking for a response to a question please use our another feedback page.
Related »

Ptsd 
8/6/13 
Treatment for PTSD And Risk of Drinking among Individuals with Alcohol Dependence
By The JAMA Network Journals
In a trial that included patients with alcohol dependence and posttraumatic stress disorder (PTSD), treatment with the drug naltrexone resulted in a decrease in the percentage of days drinking …
Therapy 
8/6/13 
Treating PTSD And Alcohol Abuse Together Doesn't Increase Drinking, Penn Study Finds
By University of Pennsylvania School of Medicine
PHILADELPHIA— Contrary to past concerns, using prolonged exposure therapy to treat patients with post-traumatic stress disorder (PTSD) and comorbid alcohol dependence does not increase drinking or cravings, Penn Medicine …
Treatment 
5/22/14 
A New Target for Alcoholism Treatment: Kappa Opioid Receptors
By Elsevier
Philadelphia, PA, May 22, 2014 – The list of brain receptor targets for opiates reads like a fraternity: Mu Delta Kappa. The mu opioid receptor is the primary target …
Naltrexone 
9/27/11 
Asians Fighting Alcoholism May Benefit from New UCLA Study
By University of California - Los Angeles
New UCLA psychology research indicates that Asians who are struggling with alcoholism may benefit especially from naltrexone, one of three medications approved by the U.S. Food and Drug Administration …
Medications 
3/17/11 
Treatment for Alcohol Dependence Might Work Best in Certain Populations, Research Suggests
By McGill University Health Centre
MONTREAL March 16, 2011 - Results from a new study suggest that one of the most prescribed medications for alcohol dependence may be more effective in some people. Preliminary …
Nalmefene 
4/11/13 
A New Treatment Option for Alcohol Dependence: Reduced Consumption Rather Than Abstinence
By Elsevier
Philadelphia, PA, April 11, 2013 – A potential new treatment for alcoholism called nalmefene is effective and safe for reducing alcohol consumption in alcohol dependent individuals, says a new …
Mason 
11/4/13 
Clinical Trial Indicates Gabapentin Is Safe And Effective for Treating Alcohol Dependence
By Scripps Research Institute
LA JOLLA, CA – November 4, 2013 – The generic drug gabapentin, which is already widely prescribed for epilepsy and some kinds of pain, appears to be safe and …
Naltrexone 
3/16/11 
Certain Populations May Benefit Most from Alcohol-dependence Treatment Naltrexone
By Alcoholism: Clinical & Experimental Research
There are few pharmacological treatments for alcohol dependence (AD). An opioid receptor antagonist called naltrexone is one of the most effective, and yet it is not effective for everyone. …
South 
1/17/12 
Comparing Alcohol Use And Other Disorders Between the United States And South Korea
By Alcoholism: Clinical & Experimental Research
Hazardous alcohol use and depression are among the 10 leading causes of disability and premature death worldwide, according to the World Health Organization. Many low- to middle-income countries have …
Xr-Ntx 
5/26/10 
Opioid-blocking Medication Reduces Brain's Response to Alcoholism Cues, McLean Hospital Study Finds
By McLean Hospital
NEW ORLEANS—Researchers at Harvard-affiliated McLean Hospital have produced the first evidence that the opioid blocker extended-release injectable naltrexone (XR-NTX) is able to reduce the brain's response to cues that …
More » 
 
© Newsline Group  |  About  |  Privacy Policy  |  Feedback  |  Mobile  |  Japanese Edition